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ABSTRACT:  1 
Background: Greater Trochanteric Pain Syndrome (GTPS) is a common cause of 2 
lateral hip pain, most commonly affecting female patients aged 40-60, and which can 3 
have a significant impact on patients’ quality of life. Extra-corporeal shockwave 4 
therapy (ESWT) alongside a structured rehabilitation programme has been shown in 5 
previous research studies to have a significant improvement in patient’s levels of pain, 6 
although it is unclear if this then leads to improved level of global functioning or 7 
activity. This case series examines the change in a range of patient reported outcome 8 
measures (PROMs) following shockwave therapy as well as the frequency of self-9 
reported side-effects. 10 
 11 
Methods: Patients undergoing extra-corporeal shockwave therapy for Greater 12 
Trochanteric Pain Syndrome were identified from case logs from a single NHS clinic. 13 
Patients completed a range of validated patient-rated outcome measures at baseline 14 
and at subsequent follow-up appointments. These include measures of pain, and 15 
measures of local hip functioning (Oxford Hip Score - OHS, Non-Arthritic Hip Score 16 
- NAHS), global functioning (EQ-5D-5L), sleep quality (Pittsburgh Sleep Quality 17 
Index - PSQI), anxiety and depressive symptoms (Hospital Anxiety & Depression 18 
Scale - HADS), and activity levels (International Physical Activity Questionnaire - 19 
IPAQ.) 20 
 21 
Results: 45 patients who completed ESWT for greater trochanteric pain syndrome 22 
were identified; with a median follow-up duration of 189 days. Side-effect incidence 23 
was low, with <10% reporting bruising, and no patients withdrew due to side-effects. 24 
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“Average” and “worst” self-reported pain values improved significantly from baseline 25 
at all time-periods studied; 6.3/10 and 8.2/10 to 3.8/10 and 5.4/10 at three-months 26 
respectively, correlating to an improvement of about a third. At three months 63% of 27 
patients were either satisfied or very satisfied, and 70% would recommend the 28 
procedure, these figures increased at six-months. Sleep quality, measures of local hip 29 
functioning, and depressive symptoms all improved consistently across different time-30 
points, however activity levels and global health markers showed less evidence of 31 
improvement. 32 
 33 
Conclusions: Extra-Corporeal Shockwave Therapy is known to be effective in 34 
patients with Greater Trochanteric Pain alongside a structured rehabilitation 35 
programme, and this case series is in keeping with the available evidence. This series 36 
demonstrates benefits across different areas of functioning. However, in this series 37 
physical activity levels did not increase even though pain decreases. As staying active 38 
has numerous health benefits further targeted intervention to address this alongside 39 
the reduction of pain may be required for optimal health outcomes. 40 
  41 
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 42 
Background 43 
Greater Trochanteric Pain Syndrome (GTPS) is a common cause of lateral hip pain, 44 
with a incidence of 1.8/1000 patients per year in primary care,[1] and accounts for 45 
20% of referrals to some orthopaedic spinal centres.[2] GTPS is commoner in women 46 
than men, and most commonly affects women in their 4th and 5th decade.[3, 4] Greater 47 
trochanteric pain is known to be commoner in patients with pre-existing low back 48 
pain, osteoarthritis of the knee (of either leg), and iliotibial band (ITB) pain, but 49 
conflicting evidence exists as to whether it is commoner in overweight or obese 50 
patients.[4, 5]  51 
 52 
Greater trochanteric pain syndrome (GTPS) has held a range of alternative names 53 
over the last few decades, indicating the on-going confusion as to the pathological 54 
processes involved. These alternative terminologies have focussed on different 55 
anatomical structures (trochanteric bursitis, or gluteus medius tendinosis), or are 56 
region based (lateral hip pain, greater trochanteric pain.) Different structures have 57 
been postulated to be involved, with attention moving away from the bursae 58 
themselves, which had been the original focus, and more towards the tendons of the 59 
abductors and external rotators, especially gluteus medius.[4, 6, 7] This varied 60 
nomenclature can cause confusion to patients and clinicians alike, and for the 61 
purposes of this article the phrase “greater trochanteric pain” will be used, although 62 
the criticisms and limitations of this terminology are accepted. 63 
 64 
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Regardless of the terms used, this condition describes an area of reproducible pain 65 
over the area of the greater trochanter, which can spread to the buttock, or upper 66 
lateral thigh with occasional spread further down the leg, and which can mimic other 67 
conditions including nerve root impingement, spinal problems or hip joint 68 
pathologies.[2, 4] Examination typically reveals maximal tenderness in the 69 
posterolateral area of the greater trochanter, however the majority of clinical tests 70 
have been found to have limited sensitivity for greater trochanteric pain and are 71 
poorly able to differentiate this from other causes of lateral hip pain.[8] Identifying 72 
those patients with lateral hip pain who do not have particular problems putting on 73 
shoes & socks (which may help to differentiate between GTPS and osteoarthritis of 74 
the hip), or those whose lateral hip pain is reproduced by the FABERs test, are 75 
thought to be the most reliable clinical questions and assessments to discriminate 76 
GTPS from other hip pain sources.[8] 77 
 78 
Imaging studies have confirmed tendinopathy of the gluteal muscles to be a common 79 
finding in patients with buttock, lateral hip and groin pain, with 88% patients with 80 
trochanteric symptoms having MRI evidence of gluteus tendinopathy compared to 81 
50% of those with hip pain but without specific trochanteric symptoms; this 82 
difference was found to be significant.[6, 9] The absence of any peritrochanteric 83 
abnormalities on MRI makes greater trochanteric pain syndrome unlikely, however 84 
these changes occur in a high proportion of patients without trochanteric pain. 85 
Caution is therefore required in interpreting imaging results in this patient cohort and 86 
may be more useful in ruling out other conditions such as osteoarthritis of the hip, or 87 
tears of the gluteal tendons.[9] 88 
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 89 
Whilst many cases of greater trochanteric pain will settle with simple conservative 90 
management options, a study based in primary care has shown that after one year 36% 91 
of patients will still suffer with trochanteric pain, and at 5 years this remains 29% 92 
indicating the chronic nature of this condition.[1] Patients who received a 93 
corticosteroid injection had a 2.7-fold chance of recovery compared to those who did 94 
not.[1] However one randomised controlled trial that sought to examine the benefits 95 
of corticosteroid injection over usual care found a significant benefit favouring 96 
injections at 3 months, but by 12months there was no benefit.[10] In addition to being 97 
significantly more expensive, there appears to be no added clinical benefit in guided 98 
versus unguided corticosteroid injections, with both often being effective in the short 99 
and medium term, and 41%-47% patients still benefitting at three months.[11] Other 100 
conservative treatment options that have been shown to be effective include 101 
physiotherapy, non-steroidal anti-inflammatory drugs, and weight loss.[4] Surgery has 102 
been tried in recalcitrant cases and there have been a range of different techniques 103 
reported with surgery focussing on the bursa, the tendinopathy, or the ITB 104 
components of greater trochanteric pain syndrome, which highlights on-going 105 
uncertainties as to the underlying pathologies in this condition.[12-14] 106 
 107 
Extra-Corporeal Shockwave Therapy (ESWT) can also be used to treat patients with 108 
trochanteric pain. This is the use of high-energy, inaudible, sound waves generated 109 
externally to the body and which are transmitted through the skin, and are often felt as 110 
vibrations. Whilst treatment doses vary, and there is  case-control study showing 111 
benefits of a single-dose of ESWT in patients with GTPS,[15] ESWT is most 112 
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typically performed over three sessions at weekly intervals in order to promote a 113 
healing response alongside a structured rehabilitation programme. [3] This has a 114 
growing evidence base in the treatment of a number of different tendinopathy 115 
conditions, of which Greater Trochanteric Pain Syndrome may be one. Currently, 116 
there is limited evidence of benefit from the use of Extra-corporeal Shockwave 117 
Therapy (ESWT) specifically in patients with trochanteric pain, with the 2011 NICE 118 
guidance (IPG 376) highlighting that overall the evidence was inconclusive.[16] 119 
There is some case-series evidence which suggests benefit of ESWT [15], and one 120 
randomised control trial found that ESWT was better than physiotherapy or 121 
corticosteroid injection at four-months, at fifteen-months there were similar results 122 
from ESWT and physiotherapy, and that both were more effective than corticosteroid 123 
injections alone.[3] A subsequent systematic review looking at evidence in arrange of 124 
lower-limb tendon conditions has suggested that ESWT may be useful in managing 125 
patients with greater trochanteric pain syndrome as an alternative to other 126 
conservative treatments such as corticosteroid injection.[17] Table 1 displays the 127 
published studies involving ESWT for Greater Trochanteric Pain Syndrome, which 128 
remain limited in number. 129 
Author 
/ Year 
Type Notes number Age 
 
f/u Result Ref 
Mani-
Babu 
2014 
Systema
tic 
Review 
2 studies – 1 
RCT, 1 case-
control study 
. . . Probably 
effective 
[17] 
NICE Review  . . . Inconclusive [16] 
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2011 
Rompe 
2009 
RCT RCT: Home 
exercise 
programme 
(HEP) v 
corticosteroid 
injection (CS) v 
ESWT (3 
sessions 
performed at 
weekly 
intervals) 
229 pts Mean  
46-50 
15 
month
s 
At 1-month 
CS > ESWT 
At 4 months 
ESWT > 
HEP / CS 
At 15 months  
HEP / ESWT 
> CS 
[3] 
Furia 
2009 
Case-
control 
Case control 
series: single-
dose ESWT v 
“additional 
forms of non-
operative 
treatment” 
66 pts . 12 
month
s 
Better 
outcomes in 
ESWT group 
[15] 
Table 1: Previous published studies investigating effectiveness of ESWT for 130 
GTPS 131 
 132 
The side-effect profile from ESWT is favourable, with few serious side-effects 133 
reported in most papers across a range of conditions treated.[18] In a placebo-134 
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controlled study of more than 270 patients, reported side-effects included transitory 135 
reddening of the skin (21%) which was harmless and did not lead to treatment 136 
cessation, pain (4.8%), and small haematomas (3%), in addition there was a 137 
possibility of ESWT triggering migraine or possible fainting.[19] The risk of 138 
haematoma was reported following the use of a non-MSK specific machine, and 139 
newer more MSK-specific ESWT devices, appear to have a safer side-effect 140 
profile.[19] Other reports of side-effects from the NICE guidance for lateral hip / 141 
trochanteric pain (IPG 376) report than in 2% of patients there was increased pain of 142 
more than 1 day following ESWT treatment, and skin irritation in 33% of patients at 1 143 
month.[16] 144 
 145 
This case series seeks to assess the frequency of side-effects seen and to quantify any 146 
changes in pain or other function measures following ESWT in an NHS clinic, and 147 
acts as an initial pilot study for further research in this area. 148 
  149 
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 150 
Methods 151 
Patients with chronic Greater Trochanteric Pain Syndrome (GTPS) treated with Extra-152 
Corporeal Shockwave Therapy (ESWT) have been treated by the authors within a 153 
single NHS Sports Medicine department in a secondary care hospital in the UK.  In 154 
line with other hospital procedures, written consent forms are used to record consent 155 
before the first session of ESWT. Patients have sessions of ESWT performed by the 156 
same practitioner, once per week for three weeks. In keeping with routine use, the 157 
energy dose is controlled by the operator to a “maximal comfortably-tolerated” 158 
energy dose which was individual for different patients, and varied between sessions. 159 
Patients are given standardised post-procedural advice and are advised to avoid 160 
NSAIDs for the day of, and a few days after, each session of ESWT. 161 
 162 
Before undergoing shockwave therapy, patients are taught to perform a structured 163 
home exercise programme including flexibility of the lower limb, lumbar mobilisation 164 
and range of movement, strengthening of the muscles around the hip including the 165 
gluteal muscles associated with GTPS, as well as core stability and proprioception 166 
exercises.[3, 20] These exercises are prompted at each of the subsequent clinic visits 167 
to promote adherence and facilitate progression. Patients are advised that these 168 
exercises can be uncomfortable, particularly to begin with, and are taught how to 169 
progress these. To support the use of the home exercise programme, patients are given 170 
written sheets discussing these exercises and reminding them of technique and how 171 
often these need to be performed for benefit. 172 
 173 
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 Data collection 174 
Patients complete a structured questionnaire about their symptoms before treatment 175 
and at each subsequent follow-up visit. These outcome measures include questions 176 
about pain, as well as a range of validated Patient-Rated Outcome Measures (PROMs) 177 
which include questionnaires about sleep quality (Pittsburgh Sleep Quality Index – 178 
PSQI), global function (EQ-5D-5L), specific hip function (Oxford Hip Score – OHS, 179 
and the Non-Arthritic Hip Score – NAHS), as well as measures of anxiety and 180 
depression symptoms (Hospital Anxiety and Depression Scale – HADS). Lastly 181 
questionnaires are used to quantify levels of physical activity. These include the short-182 
form (7-day recall) version of the International Physical Activity Questionnaire - 183 
IPAQ, and also two “vital signs” physical activity questions (“On how many days in 184 
the last week have you been at least physically active?” and “on how many minutes 185 
were you active for?” – multiplying these two figures together to give the number of 186 
active minutes in a week.) 187 
 188 
These measures are all used to examine outcomes following the ESWT procedure. 189 
Table 2 displays information for each of the PROMs in use. 190 
 191 
Outcome measure Assessing Scale Notes 
Oxford Hip Score 
(OHS) 
Measure of hip-
specific 
functioning 
Range 0-48 Higher score 
indicates better 
self-rated hip 
functioning 
Non-Arthritic Hip Measure of hip- Total NAHS Higher score 
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Score (NAHS) specific 
functioning 
score, range 0-80 indicates better 
self-rated hip 
functioning 
EQ-5D-5L Global health status Health score 
displayed, range 
0-100% 
Higher score 
indicates better 
self-rated global 
health 
Hospital Anxiety & 
Depression Scale 
(HADS) 
Measure of anxiety 
and depression 
symptoms 
Anxiety & 
Depression sub-
scales, each range 
0-21 
Lower score 
indicates fewer 
symptoms 
International 
Physical Activity 
Questionnaire 
(IPAQ) – 7-day 
recall version 
Assessment of 
physical activity 
undertaken in the 
previous 7 days 
Scores of minutes 
of activity per 
week spent 
walking, in 
moderate activity, 
and in vigorous 
activity, and in 
hours of sitting on 
a weekday 
Increased levels of 
physical activity, or 
lower levels of 
sedentary 
behaviour, are 
associated with 
significant health 
benefits. 
Pittsburgh Sleep 
Quality Index 
(PSQI) 
Sleep quality Global PSQI score 
range 0-21 
Lower score 
indicates better 
sleep quality 
Table 2: Patient-rated Outcome Measures (PROMs) used 192 
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 193 
 194 
Typically, patients are followed up three-months following ESWT, with a proportion 195 
also seen at six-weeks where appointment availability allowed. Patients are then 196 
routinely followed up after the three-month point if clinically required. 197 
 198 
The ESWT procedure is registered with the hospitals New Intervention Procedure 199 
Group (NIPAG) and data is recorded here in the format of a service evaluation project 200 
and audit; therefore formal NHS ethics permissions were not required. 201 
 202 
 Statistical analysis 203 
Data was recorded at baseline, and on an on-going basis at clinic follow-up and 204 
collated into an Excel spreadsheet (MS Excel from MS Office 2011, version 14.5.7) 205 
and analysed in SPSS (IBM SPSS Statistics, version 22). From this dataset the 206 
majority of the outcome measures are scale data.  Comparisons were made between 207 
the baseline data and data from the six-week, the three-month, and where data was 208 
present the six-month follow-up appointments. As the sample sizes were small, the 209 
Shapiro-Wilk test was used to assess normality and as the majority of the data was 210 
found to be not normally distributed the majority of the analysis was performed with 211 
non-parametric tests, typically the Wilcoxon Signed-Rank Test to look at pre/post 212 
differences. 213 
 214 
 215 
  216 
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Results 217 
A total of 46 patients who underwent Extra-Corporeal Shockwave Therapy (ESWT) 218 
for symptoms of trochanteric pain syndrome were identified from procedural logs. All 219 
patients were treated with a Chattanooga Intelect RPW rESWT machine using the 220 
manufacturer’s standard settings for GTPS (20.0Hz, 2000 shocks per session, 3 221 
treatment sessions at weekly intervals.) The energy intensity was controlled by the 222 
performing practitioner based on patient comfort. (The mean(SD) figures were 223 
ESWT1 = 2.37(0.27) bar, ESWT2 = 2.94(0.41) bar, and ESWT3 = 3.44(0.52) bar) 224 
 225 
In addition to the ESWT treatment, all patients were given a structured home exercise 226 
programme to complete with written supporting material discussing progressing this 227 
as a part of their treatment. 228 
 229 
45 patients completed all three treatment sessions of ESWT. A single patient 230 
withdrew from ESWT after their second session of treatment as she has been involved 231 
in a road traffic collision (unconnected with her trochanteric pain or the ESWT 232 
treatment) and was unable to attend the final treatment session due to her other 233 
injuries. The data for this patient was therefore removed from analysis. 234 
 235 
At least one set of follow-up results were available for all of the 45 patients that 236 
completed ESWT. Normally patients are invited for follow-up at six-weeks, and 237 
three-months following ESWT, and depending on symptoms also some are seen at 238 
six-months. Not all patients attended for a six-week appointment post-ESWT due to 239 
appointment scheduling and patient availability, with results available for 28/45 240 
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patients (62%) at the six-week time point, and 44/45 (98%) at the three-month time-241 
point, which is set as the primary outcome period. 242 
 243 
Depending on the level on on-going symptoms at three-months, some patients also 244 
had a six-month follow-up appointment booked, whereas others were left with an 245 
open appointment for them to contact the department if there were problems or 246 
questions. In total there were 27/45 responses from patients at six-months (60%), 247 
however these figures may be skewed by the presence of on-going symptoms at three-248 
months and may represent those with either poorer or slower outcomes. 249 
 250 
 Patients 251 
36 of the 45 patients (80%) who completed all three ESWT treatments for 252 
trochanteric pain were female, and the majority of both male and female patients were 253 
either overweight or obese. There was an average(SD) age of 60.9 (15.4) years, with 254 
the youngest patient being 20 and the oldest being 86 years old. There was a mean 255 
duration of symptoms of 43 months before trying ESWT, however this was skewed 256 
by two patients having symptoms for ten years prior to ESWT, with the median 257 
duration of symptoms being 30 months. 258 
 259 
Table 3 displays the demographic information for the patients in this series. Figures 260 
displayed are mean(SD) 261 
 262 
 n= Age Height 
(m) 
Weight 
(kg) 
BMI 
(kg/m2) 
%BMI 
25-30 
%BMI 
30+ 
Symptom 
duration 
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(months) 
Male 9 58.8 
(16.4) 
1.76 
(0.09) 
82.8 
(15.4) 
26.9 
(4.7) 
56% 11% 43.3 
(28.9) 
Female 36 60.3 
(15.4) 
1.60 
(0.07) 
75.9 
(12.7) 
29.6 
(4.8) 
31% 44% 43.2 
(30.5) 
         
All 45 60.0 
(15.4) 
1.64 
(0.10) 
77.4 
(13.4) 
29.0 
(4.8) 
36% 38% 43.2 
(29.8) 
Table 3: patient demographics 263 
 264 
Before ESWT was conducted, all patients had been given a home exercise 265 
programme; 91% had received formal physiotherapy input, the remainder had been 266 
given exercises and exercise sheets from other consulting healthcare professionals. 267 
There was a wide-range of treatment given prior to ESWT, with an average of 3.0 268 
corticosteroid injections given by other healthcare professionals to patients prior to 269 
referral for ESWT (range 0-8), with patients reporting an average of 3.6 weeks of 270 
benefit from their most recent injection (range 0-20 weeks). One patient had 271 
previously undergone surgery for their trochanteric symptoms one year prior to being 272 
referred for ESWT. All patients had either received an MRI or an ultrasound scan to 273 
examine the condition of the relevant muscles / tendons prior to ESWT as a part of 274 
the consideration of treatment process. 275 
 276 
 Side-effects from ESWT 277 
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The incidence of side-effects following ESWT is previously discussed and this was 278 
investigated within this case series. Overall incidence of side-effects in this series is 279 
low with 7% and 9% of patients reporting bruising at the 2nd / 3rd ESWT treatments 280 
respectively, all of which had settled by the six-week and three-month follow-up 281 
periods. No patient withdrew due to side-effects. Table 4 displays the incidence of 282 
side-effects from the NICE audit criteria for this case series. 283 
 284 
 
At 2nd 
Treatment 
At 3rd 
Treatment 
At six-
weeks 
At 
three-
months 
At six-
months 
 (n=45) (n=45) (n=28) (n=43) (n=27) 
Is there any evidence 
of local skin 
reddening over the 
treatment site? 
0% 0% 0% 0% 0% 
Is there any local 
bruising or 
haematoma over the 
treatment site? 
7% 9% 0% 0% 0% 
Is there any evidence 
of other local skin / 
soft tissue damage? 
0% 0% 0% 0% 0% 
Is there any local 0% 0% 0% 0% 0% 
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numbness of the 
treated area? 
 
Is there evidence of 
rupture of the 
structure being 
treated? 
0% 0% 0% 0% 0% 
Does the patient 
report any increased 
stiffness or worsened 
mobility following 
ESWT? 
0% 2% 0% 0% 0% 
Table 4: Incidence of side-effects following ESWT treatment 285 
 286 
 287 
 288 
 Pain scores 289 
The proportion of patients reporting themselves as pain free (VAS = 0) or virtually 290 
pain-free (VAS of 0 or 1) at six-weeks was 7% and 11% respectively, at three-months 291 
the figures were 9% and 18% respectively, and at six-months was 19% and 33% 292 
respectively. 293 
 294 
Overall there was an average reduction in pain as assessed by a 0-10 Visual Analogue 295 
Scale (VAS) from 6.3 at baseline, to 4.1 at six-weeks, 3.8 at three-months, and 3.5 at 296 
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six-months post-ESWT. These changes in pain from baseline were found to be 297 
significant at all time-points at six or more weeks. This improvement correlates to an 298 
average reduction of pain of about a third at all follow-up time points recorded.  299 
 300 
 Table 5 displays the self-reported values for “average” pain, self-reported “worst” 301 
pain and “stiffness” at baseline and follow-up appointments - all figures are 302 
mean(SD) and use a 0-10 visual analogue scale (VAS), with the significance of any 303 
changes seen being calculated from baseline values. 304 
 305 
 306 
 At 
baseline 
Before 
2nd 
ESWT 
Before 
3rd 
ESWT 
At 6 
weeks 
At 3 
months 
At 6 
months 
“Average 
Pain” 
(0-10) 
6.3 (1.7) 6.4 (1.8) 6.0 (2.0) 4.1 
(2.6) * 
3.8 
(2.7) * 
3.5 
(2.8) * 
“Worst Pain” 
(0-10) 
8.2 (1.2) x x 6.3 
(2.5) * 
5.4 
(2.9) * 
5.0 
(3.1) * 
“Average 
Stiffness” 
(0-10) 
5.3 (2.8) x x 3.7 
(3.1) * 
3.3 
(2.6) * 
2.7 
(3.0) * 
Table 5: displaying baseline and follow-up pain and stiffness scores (all marked 307 
on a 0-10 Visual Analogue Scale) 308 
 309 
The role of Extra-Corporeal Shockwave Therapy (ESWT) plus 
rehabilitation for patients with chronic Greater Trochanteric Pain 
Syndrome (GTPS), a case series assessing effects on pain, sleep quality, 
activity and functioning 
 
Page 19 
These values are displayed in the Figure 1  310 
 311 
Figure 1 – Displaying trend for self-reported “worst pain”, “average pain” and 312 
‘average stiffness” (0-10 scales) 313 
 314 
The changes in “average pain”, “worst pain” and “stiffness” were all significantly 315 
improved from baseline at all of the follow-up appointments. Although a trend of 316 
continued improvement appears to be shown in this series, for the “average pain” and 317 
“average stiffness” the differences between the figures at six-weeks and subsequent 318 
follow-ups did not reach statistical significance. For the “worst pain” there was a 319 
statistically significant improvement in pain at 6-months compared to 6-weeks, but 320 
not 3-months. These suggest that the majority of the benefits seen occur in the first 6-321 
weeks after ESWT, although benefits appear to continue beyond this point. 322 
 323 
 324 
 Sleep disturbance 325 
Sleep disturbance is a commonly reported symptom from patients with trochanteric 326 
pain syndrome, with pain sleeping on either the affected or the opposite side 327 
commonly reported. Sleep quality was assessed by means of the Pittsburgh Sleep 328 
Quality Index (PSQI), a patient self-reported questionnaire, at baseline and 329 
subsequent follow-up appointments. This questionnaire rates a number of domains of 330 
sleep quality and gives individual subs-scales as well as a global score which is 331 
displayed here for simplicity, with a lower score indicating better sleep quality 332 
overall.  333 
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 334 
The following table displays the average (SD) global PSQI results obtained at 335 
baseline and at follow-up. 336 
 Baseline 6-weeks 3-months 6-months 
PSQI (global) 10.9 (3.7) 9.7 (4.2) * 9.1 (3.7) * 9.0 (4.0) * 
Table 6: displaying the global PSQI scores at baseline and at follow-up 337 
 338 
The changes of global PSQI score from baseline to six-weeks, baseline to three-339 
months and baseline to six-months, each of between 1.2 and 1.9 points, were all found 340 
to be significant (p<0.05). However, the changes from six-weeks to either three or 341 
six-months, and three-months to six-months, were not found to be significantly 342 
different.  343 
 344 
 Local and global measures of function 345 
A range of other patient-rated outcome measures (PROMS) were used to assess 346 
outcome including several hip-region PROMS including the Non-Arthritic Hip Score 347 
(NAHS) and the Oxford Hip Score (OHS). In addition, as a marker of overall level of 348 
health status the EQ-5D-5L was used, and markers of both anxiety and depression 349 
were obtained through the use of the Hospital Anxiety and Depression Scale (HADS). 350 
 351 
Table 7 displays the mean(SD) scores for the different PROMs in use. 352 
Outcome measure Baseline 6-weeks 3-months 6-months 
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 353 
Table 7: displaying PROM data at baseline and follow-up appointments 354 
 355 
Many of the differences in scores from either baseline to six-weeks, baseline to three-356 
months, or baseline to six-months showed a significant change (p<0.05) as indicated 357 
above. The depression sub-scale of the Hospital Anxiety and Depression Scale 358 
(HADS) was significantly improved following ESWT all time points, whereas the 359 
anxiety sub-scale was only significantly different at the six-month follow-up time 360 
point. The overall health% as recorded by the EQ-5D was only improved significantly 361 
at six-weeks and six-months, but not at three-months, however the hip-specific 362 
Non-Arthritic Hip 
Score (NAHS) - total 
39.8 (12.7) 45.3 (17.2) * 50.3 (18.6) * 53.6 (19.8) * 
Oxford Hip Score 
(OHS) 
23.4 (9.0) 29.3 (10.5) * 31.9 (10.7) * 33.4 (11.1) * 
EQ-5D-5L - %health 67% (15%) 72% (13%) * 73% (19%) 77% (15%) * 
Hospital Anxiety & 
Depression Scale 
(HADS) – Anxiety 
sub-scale 
7.4 (4.3) 6.7 (4.1) 6.0 (4.0) 5.1 (3.3) * 
Hospital Anxiety & 
Depression Scale 
(HADS) – Depression 
sub-scale 
5.5 (3.0) 4.1 (2.7) * 4.4 (3.6) * 3.7 (2.7) * 
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patient-rated measures (Oxford Hip Score and the Non-Arthritis Hip Score) were both 363 
significantly improved at all time periods studied.  364 
 365 
 Activity levels 366 
Patients with trochanteric pain syndrome often report that pain is a barrier to their 367 
physical activity, therefore it may be assumed that if pain is reducing then physical 368 
activity may increase. The measure this, the rates of physical activity were recorded 369 
by using both the short form (7-day recall) International Physical Activity 370 
Questionnaire (IPAQ) and also the “Vital signs” questions discussed previously. The 371 
results are as displayed in table 8. 372 
Activity measure Baseline 6-weeks 3-months 6-months 
IPAQ 
– vigorous-level activity in 
minutes / week 
108 (379) 108 (360) 98 (342) 83 (196) * 
IPAQ 
– moderate-level activity in 
minutes / week 
242 (666) 185 (461) 233 (630) 136 (243) 
IPAQ 
– walking in minutes/ week 
362 (576) 404 (690) 463 (652) 497 (621) * 
IPAQ 
– number of hours spent sitting 
on a week day 
4.3 (3.4) 4.8 (3.0) 4.7 (3.1) 5.0 (3.0) 
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“Vital signs” 
– minutes of at least moderate 
level of activity / week 
119 (360) 68 (124) 95 (177) 80 (154) 
Table 8: displaying activity values at baseline and at follow-up 373 
 374 
The only measures of physical activity that changed significantly from baseline was 375 
decrease in the number of minutes of vigorous activity, and an increase in the number 376 
of minutes of walking (both as assessed by the short-form IPAQ) measured at six-377 
months post-ESWT compared to baseline the clinical implications of which are 378 
unclear.  379 
 380 
 Further intervention rates 381 
From the data set available, there was a median follow-up duration of 189 days for 382 
this cohort, with a maximum of 315 days. 18% of patients required consideration of 383 
further intervention as a result of persisting symptoms following ESWT, most 384 
typically review for surgical intervention or further corticosteroid injection, with 82% 385 
of this case series not requiring further intervention during the time period studied. 386 
 387 
 Overall satisfaction 388 
Overall levels of satisfaction with treatment was assessed on a 5-part Likert scale, 389 
with 63% of patients being either “satisfied” or “very satisfied” at 3-months, and at 6-390 
months this figure had increased to 75% In addition patients were asked if they would 391 
recommend the ESWT treatment to a friend or family member with the same 392 
symptoms on a four-part Likert scale. At 3-months 70% of patients would either 393 
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definitely or probably recommend the ESWT procedure, and at 6-months this figure 394 
was 80% At all time points, 7% or less would not recommend the procedure. Tables 9 395 
and 10 display the results from these two questions. 396 
 397 
 
6-weeks 
(n=18) 
3-months 
(n=40) 
6-months 
(n=24) 
Very satisfied 39% 45% 50% 
Satisfied 39% 18% 25% 
Neutral 11% 28% 17% 
Dissatisfied 6% 5% 4% 
Very dissatisfied 6% 5% 4% 
Table 9: “On the basis of your results currently, how satisfied are you 398 
with the results that you have had so far?” 399 
 400 
 401 
 
6-weeks 
(n=20) 
3-months 
(n=43) 
6-months 
(n=25) 
Yes, definitely 55% 49% 64% 
Yes, probably 20% 21% 16% 
Maybe 20% 23% 16% 
No 5% 7% 4% 
Table 10: “On the basis of your results so far, would you recommend 402 
this procedure to a friend or family member with the same symptoms?” 403 
 404 
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Discussion 405 
This case series demonstrates that the majority of patients report improvement in their 406 
symptoms. At three-months nearly two-thirds of patients are satisfied with the results 407 
of their treatment and 70% would recommend the treatment to a friend or family 408 
member with the same symptoms. The data from this case series, and the previous 409 
published work on this topic suggest that Extra-Corporeal Shockwave Therapy can be 410 
an effective treatment for a number of patients with recalcitrant Greater Trochanteric 411 
Pain Syndrome, which has not settled with other simple conservative measures, and 412 
one which is worth considering in care pathways, access permitting. Patients in this 413 
case series had a range of symptom duration and different treatments tried prior to 414 
referral for ESWT. There was no difference found in reported success or 415 
improvement in pain levels for those with symptoms of 18 months or less, compared 416 
to those with symptoms greater than 18 months suggestive that ESWT is worth 417 
considering in appropriate patients even with long-standing symptoms. 418 
 419 
Causality of benefit cannot be proven from this case series design of study alone, but 420 
these findings of improvement are in keeping with other published literature. The 421 
figures at three-months are the primary end-point with the highest proportion of 422 
respondents and patients are typically seen at six-months only if they have on-going 423 
or slow resolving symptoms or other concerns. It is possible therefore that even with 424 
the figures appearing to have improved at six-months from the three-month period, 425 
although this did not necessarily reach statistical significance, these may 426 
underestimate health benefits due to selection bias, with patients that are doing well 427 
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not returning at six-months. The magnitude of benefits may be greater than seen here, 428 
and this is worth consideration in further research.  429 
 430 
The side-effect profile reported in this case series shows that the incidence of side-431 
effects from ESWT treatment for Greater Trochanteric Pain Syndrome is relatively 432 
low, with no patients in this series failing to complete treatment due to side-effects, 433 
and less than 10% reported bruising. This is a lower figure that quoted in other 434 
sources, and this may represent the use of a modern and specific ESWT machine. 435 
 436 
This case series has demonstrated an overall average improvement of at least a third 437 
in symptoms of pain and stiffness as reported by the patients, as well as improvements 438 
in a wide range of other measures of function. The use of simple pain-scores is a very 439 
crude outcome measure, and this series has used a range of validated patient-rated 440 
outcome measures (PROMs) including specific measures of hip function, and also 441 
global measures of function. This holistic view of patient function goes far beyond the 442 
use of simple pain-rating tools and should be considered in further work to identify 443 
the most relevant outcome measures. Some measures of both local and general 444 
functioning have significantly improved, although not all reported benefits. Mood 445 
disturbance with both anxiety and depression features as assed by the Hospital 446 
Anxiety and Depression Scale (HADS) showed significant improvements at a number 447 
of time-periods. Sleep disturbance is an often-reported symptom of Greater 448 
Trochanteric Pain Syndrome, and this case series has demonstrated an improvement 449 
in sleep quality, as assessed by the PSQI questionnaire at all time-points following 450 
treatment. It is accepted that there may be confounding that exists between the various 451 
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outcome measures studied, further work may be required to examine these complex 452 
interactions in more detail. However, these outcome measures identify specific 453 
individual factors that are commonly reported by patients as problems, and it is 454 
encouraging to see improvements across a range of different domains. 455 
 456 
Physical activity has many benefits to health, and musculoskeletal pain is an often 457 
reported barrier to physical activity. Whilst the subjects in this case series had a 458 
significant improvement in their pain levels and corresponding level of functioning, 459 
they did not report a consistent improvement in activity levels. If anything the amount 460 
of vigorous activity may have decreased at the six-month period, although the amount 461 
of walking appears to have increased. It is possible that the reduction in pain seen at 462 
the same time, may be influenced by this change in activity level. Despite the 463 
reduction in pain, and positive messages being given during the rehabilitation 464 
programme about the benefits of activity, further interventions are likely to be 465 
required to increase levels of activity in order to achieve optimal health benefits in the 466 
longer term. 467 
 468 
Many of the benefits in the parameters studied improved from baseline to the six-469 
week period in particular, and whilst some improved beyond this, for several these 470 
further changes did not reach statistical significance. This is suggestive that the most 471 
benefits are gained in the early period following treatment, and it is not clear from this 472 
case series when these benefits plateau, meaning that longer-term follow-up may be 473 
helpful in identifying final outcome points. A larger series may be able to investigate 474 
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this aspect in more detail, as this series was likely to be affected by a 60% review rate 475 
at six-months. 476 
 477 
In summary this case series has demonstrated a significant improvement in both pain 478 
and a wide-range of different outcome measures in the period following extra-479 
corporeal shockwave therapy and a structured rehabilitation programme. These 480 
include a wide range of measures of patent functioning indicating improvement in a 481 
range of the symptoms that commonly affect patients with Greater Trochanteric Pain 482 
Syndrome. Further work looking at specific benefits of the shockwave itself 483 
compared to rehabilitation alone would be useful to quantify this aspect of therapy, 484 
and potentially longer-term follow-up may be helpful to see where benefits plateau, 485 
which may avoid further interventions being done at a too early time-point, and allow 486 
better quality information to be given to patients about longer-term outcomes. 487 
 488 
 489 
 490 
 Abbreviations used 491 
ESWT – Extra-Corporeal Shockwave Therapy 492 
GTPS – Greater Trochanteric Pain Syndrome 493 
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